Boceprevir dosing for late responders and null responders: The role of bridging data between treatment-naïve and -experienced subjects§


  • Potential conflict of interest: Nothing to report.

  • Data for these analyses were submitted to the United States Food and Drug Administration by Merck as part of a new drug application.

  • §

    Disclaimer: the contents of the article represent the authors' personal opinion and do not necessarily reflect any position of the Food and Drug Administration.

  • See Editorial on Page 875